Heart attacks and strokes are among the leading causes of death globally, with millions suffering from cardiovascular diseases (CVD) every year. There are more than seven million people in the UK alone, with about 100,000 patients experiencing heart attacks annually. However, a group of researchers at University College London (UCL) estimate that one 'polypill' taken daily day could eliminate a majority of these cases dramatically lowering death tolls.

The proposed polypill, a combination of a statin and three blood pressure-lowering drugs, has been under study for over two decades. Experts argue that introducing this pill universally for individuals aged 50 and above could be more effective than the current NHS Health Check, which assesses risk factors every five years for those aged between 40 and 74.

Studies have repeatedly proven the effectiveness of the polypill in preventing CVD. A groundbreaking 2019 study in The Lancet found that five years' use of the polypill cut the risk of heart attack and stroke by a third. In addition, previous modelling analyses have estimated that if given universally to people over 55, the polypill might be able to prevent 80% of heart attacks and strokes.

Today, the NHS Health Check follows a risk-based model in which patients are tested for CVD risk factors and treated with drugs accordingly. Yet, as per UCL's study, this system has serious flaws:

Low Uptake: Just 40% of those eligible for the NHS Health Check choose to have it, leaving a considerable number of at-risk patients undiagnosed and untreated.

Ineffective Prediction of Risk: The majority of heart attacks and strokes happen to people at average risk levels, thus making it challenging to identify the need for intervention effectively.

Limited Effectiveness: Even at maximum take-up, the NHS Health Check programme is predicted to have fewer health impacts compared to a polypill initiative applied to the whole population.

Simplicity and Affordability of the Polypill Strategy

One of the big benefits of the polypill is that it is so easy. In contrast to the existing screening-based model, the polypill scheme would not involve complicated medical tests or lengthy risk assessments. Instead, people reaching 50 would just have to fill out a few questions to determine possible side effects before they were prescribed.

Professor Aroon Hingorani of the UCL Institute of Cardiovascular Science, one of the strongest proponents of this scheme, says:

"Finally, the time is now to do much better on prevention. A population approach would prevent a lot more heart attacks and strokes than is done today with a strategy of trying to target a smaller group only."

Aside from the possible health implications, the polypill is also an economic solution. The drugs used are off-patent, thus cheap to produce and distribute. With the vast economic cost of managing CVD-related illnesses, a preventive model could result in substantial cost-saving for the NHS in the future.

The polypill has been proven to be effective by numerous international trials. In 2019, a randomised trial in rural Iran discovered that participants who took the polypill for five years had a 34% reduced risk of having a heart attack or stroke compared to non-participants.

Likewise, modelling research has indicated that even if only 8% of people aged over 50 took up the polypill regimen, it would still be more beneficial to their health than the NHS Health Check programme.

Is This a Case of Over-Medicalisation?

One of the main objections to the polypill strategy is the suggestion that it might result in the unnecessary medicalisation of a significant proportion of the population. But, it is argued, it should be considered as a preventative measure, not as mass medication.

Professor Sir Nicholas Wald of UCL's Institute of Health Informatics explains:

"Instead of being a 'medicalisation' of a significant proportion of the population, a polypill programme is a prevention measure to prevent an individual from becoming a patient."

He compares it with public health measures like water fluoridation or compulsory seatbelts—interventions that have been shown to have a significant impact in reducing public health danger at low individual cost.

With the evidence in favour of the polypill's effectiveness and viability overwhelming, experts are calling on the NHS to act now. It is their belief that substituting the NHS Health Check with a polypill-based prevention program could be the UK government's flagship policy under its pledge to put disease prevention ahead of cure.

As Professor Hingorani points out, "The status quo is not a justifiable option." With CVD still a major cause of death globally, taking a population-wide polypill approach could be a turning point for preventative medicine, potentially saving thousands of lives annually. The question now is whether the NHS will take up this call and establish a policy with the potential to transform the prevention of cardiovascular disease on a national level.

Kenya recently approved seven semaglutide-based drugs, expanding access to a class of drugs that has rapidly moved from diabetes treatment to one of the most talked-about weight-management therapies.

The Pharmacy and Poisons Board (PPB) said the medicines were assessed by regulatory authorities for quality, safety, and effectiveness. The move adds new options as demand for GLP-1 drugs continues to rise in the country.

Kenya Approves New Semaglutide-Based Medicines

Kenya already had Novo Nordisk’s Ozempic and Wegovy in the market. The five newly registered generic semaglutide products have been approved for treating and managing type 2 diabetes. A generic product called Truglyx was also launched in Nairobi in July.

An important thing to remember considering using these drugs is that even though they have the same active ingredient, it does not mean these medicines can be used interchangeably.

“While these products contain the same active ingredient, their approved uses are not necessarily interchangeable and must be understood with reference to the indication approved for each product,” PPB Chief Executive Officer Dr Ahmed Mohamed said.

Ozempic And Wegovy Cannot Be Used Interchangeably

Also read: GLP-1 Weight Loss Drugs Ozempic, Wegovy, Mounjaro Tied To Over 60 Reported Deaths In Australia

Although Ozempic and Wegovy contain the same active ingredient, they are not simply two names for the same treatment.

Ozempic is approved for adults with type 2 diabetes whose blood sugar is not adequately controlled, alongside diet and physical activity.

Wegovy is intended to be used for weight management in adults with a high BMI, alongside diet and exercise.

That is why the PPB has warned patients against assuming that all semaglutide products can be substituted for one another.

“While these products contain the same active ingredient, their approved uses are not necessarily interchangeable,” PPB Chief Executive Officer Dr Ahmed Mohamed said.

The regulator has also stressed that semaglutide medicines are prescription-only drugs and should be used only after assessment and prescription by a qualified healthcare professional.

Semaglutide Drugs Have Become Increasingly Popular

Also read: UK Woman Dies After Sudden Abdominal Pain Following Increase In Her Mounjaro Dose

The drugs have become popular for their ability to reduce appetite and help lose weight. But the effects of these drugs extend way beyond the weighing scale.

A 2026 analysis of the SELECT trial found semaglutide was associated with fewer hospital admissions and shorter hospital stays among people with overweight or obesity and cardiovascular disease who did not have diabetes.

At the same time, the rapid expansion of the market means there will be more competition. South Africa’s regulator was reviewing 12 generic semaglutide applications in July after patent expiry opened the door to generic competition.

Brazil also approved five new injectable semaglutide medicines last month, showing that manufacturers are rapidly responding to growing demand of GLP-1 drugs.

Are GLP-1 Drugs Completely Safe?

Just as GLP-1 medicines are steadily gaining popularity, reports emerged stating that semaglutide had the highest number of reported deaths with suspected associations, followed by Tirzepatide, Liraglutide and Dulaglutide.

62 deaths in Australia have been reported to the medicines regulator, the Therapeutic Goods Administration (TGA), with suspected associations with GLP-1 medicines, including Ozempic, Wegovy and Mounjaro.

The TGA has also received reports of nearly 3,000 serious adverse events involving these medicines, which are used by hundreds of thousands of Australians, The Herald Sun reported.

Reported adverse reactions include nausea, pancreatitis, suicidal thoughts and a rare eye condition that can cause blindness.

One of the most debated claims that sunscreen may significantly increase the risk of skin cancer is putting an old study back in focus. We took a closer look at the research and it shows a far more complicated picture than social media noise.

Study On 470,000 Participants

The controversy stems from a 2023 study based on data from more than 470,000 UK Biobank participants.

The research studied how genetic and environmental factors interact to impact the risk of skin cancer. It found that people who used sunscreen frequently had higher observed rates of melanoma, basal cell carcinoma, and cutaneous squamous cell carcinoma.

Compared to people who rarely or never reported using sunscreen, those who always used it had an observed relative risk of about 3.92 for invasive melanoma, 2.40 for basal cell carcinoma, and 2.26 for squamous cell carcinoma.

Can Sunscreen Use Contribute To Risk Of Skin Cancer?

The the crucial part of the study is that it did not establish that sunscreen directly causes skin cancer.

The observational research was primarily designed to investigate gene-environment interactions, not to test whether sunscreen causes skin cancer.

The authors themselves described the sunscreen association as surprising and discussed several possible explanations. One of them is “sunscreen paradox.”

Also read: Scientists Find Rare Contagious Skin Cancer In Fish From US, Canada: Should Humans Worry?

What Is The 'Sunscreen Paradox'?

People who spend more time outdoors, have accumulated more UV exposure, or already have a higher risk of skin cancer may be more likely to use sunscreen in the first place. Sunscreen use can therefore become a marker of higher sun exposure rather than the cause of the cancer.

Lead author Ivan Litvinov told AAP FactCheck that the viral interpretation had misrepresented the findings. “The post misinterpreted the results of our study,” he said.

Litvinov also explained that sunscreen can create a false sense of security when people use too little, fail to reapply it or treat it as permission to stay in the sun longer. This indirectly contributes to the risk of skin cancer. “When sunscreen is used as a ‘permission to tan’, problems arise,” he said.

Should You Stop Using Sunscreen?

Current evidence does not support the conclusion that one must stop using sunscreen to avoid skin cancer.

A randomized trial based on 1,621 adults in Australia found that regular sunscreen use was linked with fewer melanomas over long-term follow-up. Invasive melanoma was substantially lower among those assigned to daily sunscreen use.

More recently, a 2026 review of photoprotection concluded that daily sunscreen use reduces actinic keratoses and cutaneous squamous cell carcinoma in high-risk people, although evidence for basal cell carcinoma and melanoma prevention is more heterogeneous.

Also read: How Vitamin D Helps Protect Your Skin And Lower Cancer Risks Naturally

How Can You Protect Your Skin Without Using Sunscreen?

While sunscreen is important, one must follow some other steps to ensure complete protection. Here are some tips you should remember according to American Academy of Dermatology Association.

Find Your Shade

The sun's rays are most powerful between 10 a.m. and 2 p.m. During these hours, it's best to seek shade. A good rule of thumb: if your shadow is shorter than you are, the sun is very strong, and you should definitely look for some cover.

Dress For Sun Protection

Whenever you can, wear sun-protective clothing. This means choosing things like a lightweight, long-sleeved shirt, long pants, a wide-brimmed hat, and sunglasses with UV protection.

For even better defense, look for clothing labels that have an Ultraviolet Protection Factor (UPF) number, which tells you how much UV radiation the fabric blocks.

Say No To Tanning Beds

Both the sun and tanning beds give off harmful ultraviolet (UV) light, which can cause skin cancer and wrinkles. It's best to avoid tanning beds completely.

If you want to have a tanned look, consider using a self-tanning product instead, but remember to still use sunscreen along with it for actual sun protection.

Be Extra Careful Near Reflective Surfaces

You need to be especially cautious when you're near water, snow, or sand. These surfaces are highly reflective, meaning they bounce back the sun's damaging rays, which can significantly increase your chance of getting a sunburn.

COVID-19 is surging in some parts of California as wastewater surveillance showing a sharp rise in the amount of virus circulating in the surrounding communities.

The latest data comes as California health officials warn that the state’s COVID-19 pattern appears to be shifting, with summer outbreaks becoming more prominent than winter ones.

According to the California Department of Public Health data cited by the San Francisco Chronicle, COVID-19 outbreak expanded in June, rose through July and continued rising in August. Hospital admissions are also increasing, although they remain relatively low compared to previous outbreaks.

WastewaterSCAN data showed that COVID-19 concentrations across monitored Bay Area sites were 136% higher in July than in June. By early August, nearly 54% of monitored sites were classified as having “high” levels, with San Francisco, San Jose, Sunnyvale, San Rafael, Vallejo and Napa among the communities reporting high levels of cases.

“Monitoring wastewater can act as an early warning system for health officials and the public,” said Amanda Bidwell, WastewaterSCAN’s scientific program manager.

Wastewater Surveillance Reveals COVID-19 Resurgence

Wastewater surveillance looks for traces of SARS-CoV-2 in sewage. Because infected people can shed the virus even when they have mild or no symptoms, wastewater can provide an early picture of infections spreading through a community.

The CDC says wastewater trends can detect viruses earlier than clinical testing and can also capture infections that never result in a doctor's visit. An increase in wastewater viral activity may therefore signal a higher risk of infection in the community.

California is currently one of only four U.S. states where COVID-19 wastewater activity is classified as moderate or high by the CDC, according to the Los Angeles Times. The CDC also says COVID-19 is growing or likely growing in 43 states.

Also read: BMJ Public Health Retracts Controversial COVID Vaccine Study Cited In US Senate Hearing

Is A Dangerous New COVID Variant Causing The Surge?

Wastewater monitoring suggests several variants are circulating rather than one strain. In the Bay Area, XFG, also known as “Stratus,” remains prominent, while NB.1.8.1, or “Nimbus,” is also circulating.

Stanford infectious disease expert Dr. Abraar Karan said there is currently no evidence suggesting a dangerous or different virus or a variant that is expected to cause a major increase in hospitalizations or causalties.

Experts say the current wave should not be confused with the severe COVID-19 surges of the pandemic's early years. According to recent data and reports, hospitalizations remain comparatively low compared to previous outbreaks.

However, California health officials are urging people who have not received the 2025-26 COVID-19 vaccine to consider getting it now rather than waiting for the updated vaccine expected later this year.

“Summer is really the bigger peak,” California Public Health Officer Dr. Erica Pan said. “Go ahead and get it now, given the surge.”

The timing could become important as schools reopen and people spend more time in crowded indoor settings. In 2025, California's summer COVID-19 wave peaked later in the season, meaning the current increase may not be over yet.